Biotech · Private company
Prevail Therapeutics
Track this companyFree. Adds Prevail Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials55 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- LY3884961Phase 2 · Gaucher DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LY3884961Phase 2 · Gaucher Disease, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- LY3884961Phase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LY3884963Phase 2 · Frontotemporal DementiaClinicalTrials.gov · fetched Nov 12, 2026
- MethylprednisolonePhase 2 · Gaucher Disease, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- MethylprednisolonePhase 2 · Frontotemporal DementiaClinicalTrials.gov · fetched Nov 12, 2026
- MethylprednisolonePhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Optional PrednisonePhase 2 · Frontotemporal DementiaClinicalTrials.gov · fetched Nov 12, 2026
- Optional SirolimusPhase 2 · Frontotemporal DementiaClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 2 · Gaucher Disease, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- SirolimusPhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SirolimusPhase 2 · Gaucher Disease, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- LY3962681Phase 1 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's DiseasePHASE1 · RECRUITING · started Aug 27, 2024ClinicalTrials.gov NCT06565195 · fetched Nov 12, 2026
- A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 20, 2022ClinicalTrials.gov NCT05487599 · fetched Nov 12, 2026
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 29, 2021ClinicalTrials.gov NCT04411654 · fetched Nov 12, 2026
- Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 9, 2020ClinicalTrials.gov NCT04408625 · fetched Nov 12, 2026
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 3, 2020ClinicalTrials.gov NCT04127578 · fetched Nov 12, 2026